Exogenous application of plant growth regulators induce chilling tolerance in direct seeded super and non-super rice seedlings through modulations in morpho-physiological attributes

Recently, super rice has gained much importance due to its high yield potential while exogenous application of plant growth regulators (PGRs) is an important aspect in plant development and defense responses under stress conditions. In this study we conducted two pot experiments. Firstly, four super rice cultivars, viz. Peizataifeng, Huayou 213, Yuxiangyouzhan and Huahang 31 were subjected to a series of five chilling temperatures, i.e. 11 °C, 12 °C, 13 °C, 14 °C and 15 °C (day/night) for about 25–27 days. Secondly, seeds of Peizataifeng (super rice) and Yuejingsimiao 2 (non-super rice) were then treated with different combinations of salicylic acid (SA), brassinolide (BR), calcium chloride (CaCl2) and fulvic acid (FA) and then exposed to chilling stress at 13 °C for four days. Resultantly, Peizataifen (super rice) was found with the lowest seedling survival rate at all chilling temperatures among all four super rice cultivars, however, it was still found more resistant when compared with Yuejingsimiao 2 (non-super rice) in the second experiment. Furthermore synergistic effect of all PGRs alleviated low temperature stress in both rice cultivars by improving seedling survival rates, leaf area, seedling dry weight, seedling height, root morphology and by modulating antioxidant enzymes, improving proline content and lowering lipid peroxidation

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Thermodynamic optimization in laminar and fully developed flow in double pipe heat exchanger with arrow-shaped extended surfaces: A novel design

An innovative design of extended fins in the form of arrow fins is optimized for high performance heat transfer in a double pipe heat exchanger (DPHX). The arrow fins are designed within the trapezoidal fin to save material, weight, cost and making energy-efficient DPH. The arrow fins are investigated for the first time in DPHX. The FEM approach is used for computational simulation of the present work. A thermal boundary condition of constant heat flux is imposed on the arrow fins and inner pipe assembly. The results are computed in terms of fRe, Nusselt number and j-factor. The results dictate that the geometrical configurations of arrow DPHX for a significant rise in the values of the Nusselt number are: 80 % height of arrow fins is recommended when the number of arrow fins varies from 6 to 24, 20 % height for 30 arrow fins in the case of smaller values of radii ratio (Rˆ). For larger values of Rˆ, 20 % height of arrow fins may be selected for M=6&30, while for arrow fins varying from 12 to 24, H*=0.8 is recommended. On comparison of the thermal performance of the arrow-finned DPHX with the trapezoidal-finned DPHX, the maximum rise of the Nusselt number and j-factor are 113.2 % and 124.2 %, respectively. The proposed design of arrow-finned DPHX has advantages over the design of trapezoidal finned DPHX due to the significant decrease both in manufacturing cost and weight, increased thermal performance, and saving energy

Nitrogen use and crop performance of rice under aerobic conditions in a semiarid subtropical environment

Aerobic rice (Oryza sativa L.) is gaining in popularity across South Asia, mainly because it saves water and labor. Under warm (sub) tropical conditions of this region, this unconventional system aimed at improved resource use efficiency is still in the development phase. We tested crop performance and N uptake of three local genotypes in relation to di¬fferent water and N supply rates under aerobic conditions at the research station of the University of Agriculture, Faisalabad, Pakistan. In field experiments during 2009 to 2010, covering two rice seasons, three irrigation levels (high, moderate, and low), three N rates (0, 170, and 220 kg N ha–1), and three genotypes (KSK133, IR6, and RSP1), crop performance and total N uptake (TNU) were strongly influenced by irrigation and di¬ffered among genotypes. At the highest level of irrigation, genotype KSK133 performed better than RSP1 and IR6, resulting in an accumulated aboveground biomass of 13 Mg ha–1 and a grain yield of 5 Mg ha–1. The TNU ranged from 34 to 126 kg ha–1 in 2009 and from 52 to 123 kg ha–1 in 2010. For all genotypes, we observed a strong positive correlation between TNU and grain yield. Surprisingly, the N application rate did not influence TNU, but the high irrigation regime increased TNU. The limited response to N application suggests significant losses of the applied N. This highlights the need for careful N management in aerobic rice systems; N application should match periods of sufficient soil moisture availability and the greatest crop N demand